Predictive Financial Statements From 2010 to 2025

POAI Stock  USD 0.79  0.01  1.28%   
Predictive Oncology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Predictive Oncology's valuation are provided below:
Gross Profit
880.4 K
Market Capitalization
7.6 M
Enterprise Value Revenue
3.7188
Revenue
1.7 M
Earnings Share
(1.43)
We have found one hundred twenty available trending fundamental ratios for Predictive Oncology, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Predictive Oncology recent fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The Predictive Oncology's current Enterprise Value is estimated to increase to about 11.7 M, while Market Cap is projected to decrease to under 4.2 M.

Predictive Oncology Total Revenue

955,099

Check Predictive Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Predictive Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 415.4 K, Interest Expense of 12.9 M or Selling General Administrative of 7.1 M, as well as many indicators such as Price To Sales Ratio of 2.62, Dividend Yield of 0.0 or Days Sales Outstanding of 91.54. Predictive financial statements analysis is a perfect complement when working with Predictive Oncology Valuation or Volatility modules.
  
Build AI portfolio with Predictive Stock
Check out the analysis of Predictive Oncology Correlation against competitors.
For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.

Predictive Oncology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.3 MM9.5 M
Slightly volatile
Short and Long Term Debt Total1.9 M2.1 M1.9 M
Slightly volatile
Other Current Liabilities1.6 M1.6 M1.6 M
Slightly volatile
Total Current LiabilitiesM3.6 M3.9 M
Slightly volatile
Property Plant And Equipment Net1.3 M2.4 M1.3 M
Slightly volatile
Accounts Payable1.1 M1.1 MM
Pretty Stable
Cash697.9 K734.7 K4.3 M
Slightly volatile
Non Current Assets TotalM2.7 M4.1 M
Slightly volatile
Cash And Short Term Investments697.9 K734.7 K4.4 M
Slightly volatile
Common Stock Total Equity275.4 K178.2 K329.3 K
Slightly volatile
Common Stock Shares Outstanding5.7 M5.5 M1.4 M
Slightly volatile
Liabilities And Stockholders Equity9.3 MM9.5 M
Slightly volatile
Other Current Assets347.2 K360 K349.3 K
Slightly volatile
Other Stockholder Equity189.2 M180.2 M86.5 M
Slightly volatile
Total Liabilities4.6 M5.2 M4.4 M
Slightly volatile
Property Plant And Equipment Gross4.7 M4.5 MM
Slightly volatile
Total Current Assets2.1 M2.2 M5.2 M
Slightly volatile
Short Term Debt1.5 M1.1 M1.6 M
Pretty Stable
Intangible Assets199.6 K210.1 K858 K
Slightly volatile
Common Stock63.3 K66.7 K364.7 K
Pretty Stable
Net Receivables782.8 K745.6 K307.4 K
Slightly volatile
Inventory307 K385.7 K269.5 K
Slightly volatile
Capital Surpluse70.3 M127.5 M68.6 M
Slightly volatile
Property Plant Equipment1.7 M2.4 M1.3 M
Slightly volatile
Other Liabilities21.7 K22.9 K202 K
Slightly volatile
Other Assets64.7 K68.1 K821.7 K
Slightly volatile
Short and Long Term Debt128.6 K135.4 K1.5 M
Slightly volatile
Capital Stock64.1 K67.5 K198.1 K
Pretty Stable
Capital Lease Obligations1.5 M2.1 MM
Slightly volatile
Preferred Stock Total Equity634713777
Slightly volatile
Non Current Liabilities Other22.3 K23.5 K167.2 K
Slightly volatile

Predictive Oncology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization415.4 K695.7 K426.9 K
Slightly volatile
Selling General Administrative7.1 M7.4 M7.1 M
Slightly volatile
Selling And Marketing Expenses953.4 K1.5 M942.6 K
Slightly volatile
Other Operating Expenses9.8 M11.7 M9.9 M
Slightly volatile
Total Operating Expenses9.5 M11.7 M9.6 M
Slightly volatile
Total Revenue955.1 K1.6 M927.9 K
Slightly volatile
Gross Profit594.3 K797.7 K577.4 K
Slightly volatile
Cost Of Revenue867.4 K826.1 K382.2 K
Slightly volatile
Research Development205.7 K216.6 K628.1 K
Pretty Stable
Reconciled Depreciation854.1 K695.7 K472.9 K
Slightly volatile
Interest Income4.4 M6.6 M3.8 M
Slightly volatile
Preferred Stock And Other Adjustments443.4 K498.9 K543.9 K
Slightly volatile
Non Recurring10.3 M11.6 M12.6 M
Slightly volatile

Predictive Oncology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow4.4 M8.7 M4.5 M
Slightly volatile
Depreciation415.4 K695.7 K426.9 K
Slightly volatile
Total Cash From Financing Activities3.7 M3.9 M7.8 M
Pretty Stable
End Period Cash Flow697.9 K734.7 K4.3 M
Slightly volatile
Stock Based Compensation257.8 K271.3 K2.1 M
Slightly volatile
Change To Netincome13.5 M12.9 M5.5 M
Slightly volatile
Change Receivables55.9 K62.9 K68.6 K
Slightly volatile
Dividends Paid679715B
Slightly volatile
Cash And Cash Equivalents Changes422 K474.8 K517.6 K
Slightly volatile
Cash Flows Other Operating739.8 K832.2 K907.4 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.622.75432.5668
Slightly volatile
Days Sales Outstanding91.54168118
Very volatile
Average Payables769.1 KM1.1 M
Pretty Stable
Stock Based Compensation To Revenue0.190.16946.068
Slightly volatile
Capex To Depreciation0.0130.01375.3358
Slightly volatile
Inventory Turnover2.252.14181.3363
Slightly volatile
Days Of Inventory On Hand162170346
Slightly volatile
Payables Turnover0.760.72280.4598
Slightly volatile
Sales General And Administrative To Revenue4.344.569417.5387
Slightly volatile
Average Inventory229.1 K389.9 K272.9 K
Slightly volatile
Research And Ddevelopement To Revenue0.09040.09520.5565
Very volatile
Capex To Revenue0.00560.00590.2425
Slightly volatile
Cash Per Share0.130.13471.2 K
Slightly volatile
Days Payables Outstanding4805053.9 K
Slightly volatile
Income Quality1.061.01050.6465
Slightly volatile
Intangibles To Total Assets0.04010.04230.1926
Pretty Stable
Current Ratio0.590.61941.7683
Slightly volatile
Receivables Turnover2.072.1785.6473
Pretty Stable
Capex Per Share0.00170.001798.4996
Slightly volatile
Average Receivables537.2 K511.6 K465.9 K
Pretty Stable
Revenue Per Share0.280.2977117
Slightly volatile
Interest Debt Per Share0.370.39072.3 K
Slightly volatile
Debt To Assets0.410.42860.7723
Slightly volatile
Operating Cycle498338479
Slightly volatile
Days Of Payables Outstanding4805053.9 K
Slightly volatile
Ebt Per Ebit0.940.99283.4996
Pretty Stable
Quick Ratio0.490.51211.6769
Slightly volatile
Net Income Per E B T1.471.291.3841
Slightly volatile
Cash Ratio0.190.20451.4258
Slightly volatile
Days Of Inventory Outstanding162170346
Slightly volatile
Days Of Sales Outstanding91.54168118
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00091.0393
Very volatile
Fixed Asset Turnover0.630.66717.0236
Slightly volatile
Debt Ratio0.410.42860.7723
Slightly volatile
Price Sales Ratio2.622.75432.5668
Slightly volatile
Asset Turnover0.290.32660.2785
Slightly volatile
Gross Profit Margin0.460.49120.5802
Slightly volatile

Predictive Oncology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.2 M4.5 M11.5 M
Pretty Stable
Enterprise Value11.7 M5.9 M10.1 M
Very volatile

Predictive Fundamental Market Drivers

Cash And Short Term Investments734.7 K

Predictive Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Predictive Oncology Financial Statements

Investors use fundamental indicators, such as Predictive Oncology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Predictive Oncology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue305 K320.2 K
Total Revenue1.6 M955.1 K
Cost Of Revenue826.1 K867.4 K
Stock Based Compensation To Revenue 0.17  0.19 
Sales General And Administrative To Revenue 4.57  4.34 
Research And Ddevelopement To Revenue 0.10  0.09 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.30  0.28 
Ebit Per Revenue(6.74)(7.07)

Currently Active Assets on Macroaxis

When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:
Check out the analysis of Predictive Oncology Correlation against competitors.
For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.43)
Revenue Per Share
0.278
Quarterly Revenue Growth
21.707
Return On Assets
(0.73)
Return On Equity
(4.90)
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.